peptides - Page 2 of 2 - EpiVax, Inc. - Informatics and Immunology

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final

Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

by Annie De Groot | May 15, 2019

EpiVax_TaspoglutidePoster_14May19

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018

EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release

HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

by Annie De Groot | Oct 5, 2018

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

Recent Posts

Categories